Quantum Science to Exhibit at INFIQ® technology at Mobile World Congress 2023

Nanomaterials leader Quantum Science is preparing to showcase its INFIQ® quantum dot technology ahead of an exhibit at the world’s largest connectivity event.

Quantum Science is delighted to announce it has joined the UK trade mission for this year’s Mobile World Congress (MWC) exhibition in Barcelona.

The event, which runs from 27 February – 2 March at the Fira Gran Via, will see Quantum Science’s ground-breaking INFIQ® quantum dots displayed on a stand by the UK Government’s Department for International Trade (DIT).

Quantum Science will also feature in this year’s DIT UK Company Directory, which promotes innovative UK companies that have seen success on the international trading stage.

As well as appearing at the exhibit, Quantum Science’s leadership team will be in attendance, and is looking forward to meeting delegates and sharing the latest in high-performance quantum dot technology.

Dr Hao Pang, CEO and Founder of Quantum Science, said: “We’re really looking forward to attending MWC Barcelona this year and sharing the revolutionary science behind our INFIQ® quantum dots. This technology makes high-performance short-wave infrared sensing a reality and is already unlocking exciting new applications in consumer electronics markets, from smartphones sensors to car safety features. It’s set to be a great event and we can’t wait to see the other amazing technologies that will be on show!”

The MWC is an annual event that highlights the latest innovative technologies that will advance industries worldwide.

This year’s event will feature five key themes, focusing on 5G acceleration, Reality+, OpenNet, Digital Everything, and FinTech.

It is expected that more than 80,000 people will attend the conference from over 200 countries worldwide.

To arrange a meeting with the Quantum Science team at MWC23, contact info@qscis.com

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version